Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisArun J. Sanyal, Patricia R. Robuck, Jay H. Hoofnagle et al.|New England Journal of Medicine|2010Cited by 3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialBrent A. Neuschwander‐Tetri, Edward Doo, Rohit Loomba et al.|The Lancet|2014Cited by 2.2k
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 DiabetesRena R. Wing, Xavier Pi‐Sunyer, George L. Blackburn et al.|Diabetes Care|2007Cited by 1.5k
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver DiseaseArun J. Sanyal, James Tonascia, Mark L. Van Natta et al.|New England Journal of Medicine|2021Cited by 1.1k
Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trialRena R. Wing, Edward W. Gregg, John M. Jakicic et al.|The Lancet Diabetes & Endocrinology|2016Cited by 728